Rocky Mountain Movement Disorders Center | Englewood, CO
Status and phase
Conditions
Treatments
About
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
Full description
This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Open-label Extension Entry Criteria
Key Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
64 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal